BOSTON--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...

SonoThera to Present at ASN Kidney Week 2024 Demonstrating the Potential of Novel Nonviral Ultrasound-Mediated Gene Therapy ...

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

Rossetti S, Consugar MB, Chapman AB, et al.: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143–60 CrossRef CrossRef e3. Hateboer N, v ...

APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

—Researchers recently set out to learn which factors predict rapid decline in patients with autosomal dominant polycystic kidney disease (ADPKD), and how this information could help clinicians ...

Detailed price information for Xortx Therapeutics Inc (XRTX-X) from The Globe and Mail including charting and trades.

"We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro." JIC Venture Growth Investments ...

Regulus (RGLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and ...